Henry Schein (NASDAQ:HSIC – Get Free Report) had its price target hoisted by analysts at Morgan Stanley from $64.00 to $68.00 in a report issued on Tuesday, Benzinga reports. The brokerage presently has an “underweight” rating on the stock. Morgan Stanley‘s price objective points to a potential downside of 19.96% from the stock’s previous close.
HSIC has been the topic of a number of other research reports. Citigroup reaffirmed a “buy” rating and issued a $112.00 price target (up from $100.00) on shares of Henry Schein in a report on Wednesday, August 5th. Leerink Partners set a $92.00 price objective on Henry Schein and gave the company a “market perform” rating in a report on Wednesday, October 14th. Wall Street Zen raised Henry Schein from a “hold” rating to a “buy” rating in a research report on Monday, August 17th. UBS Group raised their target price on Henry Schein from $94.00 to $95.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 4th. Finally, Barclays restated an “overweight” rating and issued a $100.00 target price (up from $86.00) on shares of Henry Schein in a research note on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $93.86.
Check Out Our Latest Report on Henry Schein
Henry Schein Stock Performance
NASDAQ HSIC opened at $84.96 on Tuesday. The company has a market capitalization of $9.39 billion, a PE ratio of 23.28, a price-to-earnings-growth ratio of 1.51 and a beta of 0.87. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.76 and a current ratio of 1.33. Henry Schein has a 52-week low of $68.70 and a 52-week high of $92.18. The company has a 50-day simple moving average of $85.81 and a 200 day simple moving average of $81.59.
Henry Schein (NASDAQ:HSIC – Get Free Report) last released its earnings results on Tuesday, November 3rd. The company reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.36 by $0.20. The firm had revenue of $3.47 billion for the quarter, compared to analysts’ expectations of $3.48 billion. Henry Schein had a net margin of 3.07% and a return on equity of 16.39%. The company’s quarterly revenue was up 4.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.38 earnings per share. On average, research analysts predict that Henry Schein will post 5.55 EPS for the current year.
Institutional Trading of Henry Schein
Several hedge funds and other institutional investors have recently modified their holdings of HSIC. Public Employees Retirement System of Ohio purchased a new stake in Henry Schein during the 2nd quarter worth about $2,547,000. Buckland Partners Management Co LLC purchased a new position in Henry Schein during the 2nd quarter valued at about $1,036,000. California State Teachers Retirement System grew its holdings in Henry Schein by 16.3% during the 1st quarter. California State Teachers Retirement System now owns 123,992 shares of the company’s stock valued at $9,138,000 after buying an additional 17,418 shares in the last quarter. Redwood Investment Management LLC purchased a new position in Henry Schein during the 2nd quarter valued at about $1,167,000. Finally, Quantinno Capital Management LP increased its position in shares of Henry Schein by 15.7% during the first quarter. Quantinno Capital Management LP now owns 108,653 shares of the company’s stock valued at $8,008,000 after buying an additional 14,756 shares during the period. Institutional investors own 96.62% of the company’s stock.
Top Henry Schein Stories
Here are a few of the latest stories about HSIC:
- Neutral Sentiment: Henry Schein expects 2026 revenue of $13.8 billion to $13.9 billion, broadly in line with the $13.8 billion consensus estimate. Henry Schein lowers 2026 adjusted EPS guidance following change to non-GAAP reporting
- Negative Sentiment: 2026 adjusted EPS guidance is now $5.42–$5.48, below the cited analyst consensus of $5.54. The lowered outlook is the main potential pressure on HSIC shares, though the company linked the update to its non-GAAP reporting presentation. Henry Schein cuts FY2026 non-GAAP EPS guidance on accounting change
Henry Schein Company Profile
Henry Schein, Inc. is a global distributor of health care products and services, serving dental and medical practitioners, veterinary professionals, and other health care organizations. The company traces its roots to a pharmacy founded by Henry and Esther Schein in Queens, New York, in 1932. Its offerings include medical and dental supplies, equipment, pharmaceuticals, vaccines, and diagnostic products. Henry Schein also provides practice-management software, technology solutions, and business services designed to help health care professionals manage their operations.
Further Reading
- Five stocks we like better than Henry Schein
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.
